Ticker: LPCN

Lipocine Inc. (NASDAQ: LPCN) has recently published its quarterly report for the period ended June 30, 2025. Here are key points extracted from the income statement and additional financial insights: Revenue: License Revenue: $500,000 recognized in Q2 2025 compared to $0 in Q2 2024. Royalty Rev...

Company Overview Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company focusing on oral delivery solutions for poorly bioavailable drugs, with notable products aimed particularly at hormone replacement therapies and neuropsychiatric disorders. The company has made strides with its lead prod...